2.1633

0.93% 0.0233

Palisade Bio Inc (PALI)

Overview News Price History Financials Discussions Forecast Stock Split

Palisade Bio Inc stock is traded at $2.1633, with a volume of 1.00M. It is up +0.93% in the last 24 hours and up +9.64% over the past month. Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.

Previous Close:

$2.14

Open:

$2.13

24h Volume:

1.00M

Relative Volume:

0.33

Market Cap:

$376.42M

Revenue:

$250.00K

Net Income/Loss:

$-24.15M

P/E Ratio:

-2.0301

EPS:

-1.0656

Net Cash Flow:

$-12.40M

1W Performance:

+2.86%

1M Performance:

+9.64%

6M Performance:

+27.06%

1Y Performance:

+169.66%

1-Day Range:

$2.10

$2.22

1-Week Range:

$1.95

$2.22

52-Week Range:

$0.53

$2.855

Palisade Bio Inc Stock (PALI) Company Profile

Name

Palisade Bio Inc

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

(858) 704-4900

Address

7750 EL CAMINO REAL, SUITE 5200, CARLSBAD

Employee

Twitter

Next Earnings Date

2026-08-10

Latest SEC Filings

PALI's Discussions on Twitter

Compare PALI vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PALI Palisade Bio Inc	2.16	372.94M	250.00K	-24.15M	-12.40M	-1.0656
VRTX Vertex Pharmaceuticals Inc	515.44	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	806.90	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	992.82	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	215.68	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.27	39.31B	5.76B	514.49M	1.10B	4.4813

Palisade Bio Inc Stock (PALI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-09-26	Initiated	Wolfe Research	Outperform
Mar-26-26	Initiated	H.C. Wainwright	Buy
Feb-25-26	Initiated	Stifel	Buy
Jan-09-26	Initiated	B. Riley Securities	Buy
Dec-29-25	Initiated	Piper Sandler	Overweight

Palisade Bio Inc Stock (PALI) Latest News

07:27 AM

Weekly Recap: Cash runway to Phase 2 readouts and Q2 loss, stock outlook - TradingView

07:27 AM

02:05 AM

FY2030 EPS Estimates for Palisade Bio Reduced by Analyst - MarketBeat

02:05 AM

Aug 14, 2026

Palisade Bio (PALI): Commodore Capital group now reports 0.0% beneficial ownership - Stock Titan

Aug 14, 2026

Palisade Bio, Inc. (NASDAQ:PALI) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat

Aug 14, 2026

Maxim Group Maintains Palisade Bio(PALI.US) With Buy Rating, Maintains Target Price $8 - Moomoo

Aug 14, 2026

Aug 13, 2026

Palisade Bio (PALI): Soleus group reports 7.5% stake, 13.1M shares held - Stock Titan

Aug 13, 2026

HC Wainwright Has Weak Forecast for Palisade Bio Q3 Earnings - MarketBeat

Aug 13, 2026

Aug 12, 2026

Palisade Bio (PALI) Receives a Buy from Oppenheimer - The Globe and Mail

Aug 12, 2026

Aug 11, 2026

Oppenheimer Maintains Palisade Bio(PALI.US) With Buy Rating, Maintains Target Price $8 - Moomoo

Aug 11, 2026

Aug 10, 2026

Palisade Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 10, 2026

Palisade Bio plans phase 2 ulcerative colitis trial in 2H 2026 - Investing.com Australia

Aug 10, 2026

Palisade Bio Q2 loss widens to $10.6M as R&D costs surge for lead candidate - scanx.trade

Aug 10, 2026

Palisade Bio (NASDAQ:PALI) Releases Quarterly Earnings Results, Hits Expectations - MarketBeat

Aug 10, 2026

Palisade Bio Reports Q2 2026 Results, Advances PALI-2108 Into Phase 2 Development for Ulcerative Colitis and Crohn’s Disease - Quiver Quantitative

Aug 10, 2026

Palisade Bio Q2 net loss widens on higher R&D costs - TradingView

Aug 10, 2026

Palisade Bio Reports Second Quarter 2026 Financial Results - GlobeNewswire

Aug 10, 2026

PALISADE BIO, INC. Q2 2026: Revenue $0.5M, EPS $(0.05) — 10-Q Summary - TradingView

Aug 10, 2026

Renaissance Technologies LLC Lowers Stake in Palisade Bio, Inc. $PALI - MarketBeat

Aug 10, 2026

Aug 09, 2026